ARTICLE | Clinical News
IL13-PE38 (IL-I3 PE38QQR): Began Phase I/II trial
December 18, 2000 8:00 AM UTC
NeoPharm Inc. (NEOL), Bannockburn, Ill. Product: IL13-PE38 (IL-I3 PE38QQR) Business: Cancer Therapeutic category: Cytotoxic Target: IL-13 receptor on cancer cells Description: Fusion protein of inte...